Skip to main content

Table 1 Patient characteristics

From: Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

Characteristic

Number (n = 10)

%

Age in years, mean (range)

67 (48–79)

 

Biopsy of primary tumour

  

 ER+/AR+

10

100

Biopsy of metastases

 ER+/AR+

8

80

 ER+/AR-

1

10

 ER−/AR−

1

10

Previous treatment lines

 0–1

3

30

 2–4

7

70

Visible lesions: total, median per patient (range)

120, 9 (2–32)

 

 Conventional imaging (CT, bone scan)

69 (54, 40)

58 (45, 33)

 Visible on PET alone ([18F]FES or [18F]FDHT PET)

51 (33, 20)

42 (28, 16)

  Total visible on [18F]FES PET (observer 1, 2)

64, 69

53, 58

  Total visible on [18F]FDHT PET (observer 1, 2)

36, 37

30, 31

Location

 Bone (conventional imaging, [18F]FES, [18F]FDHT PET)

79 (55, 45, 37)

66 (80, 54, 64)

 Lymph node (conventional imaging, [18F]FES; [18F]FDHT PET)

30 (8, 29, 16)

25 (12, 35, 28)

 Viscerala (conventional imaging, [18F]FES, [18F]FDHT PET)

11 (6, 9, 5)

9 (9, 11, 9)

  1. aExcluding liver